Leishmanicidal activity of films containing paromomycin and gentamicin sulfate both in vitro and in vivo

Iranian Journal of Parasitology

Volumn 6, Issue 3, 2011, Pages 60-65

  Tolouei, S ^a   Hasheminia, S J ^a   Narimani, M ^a   Khamesipour, A ^c   Shatalebi, M A ^b   Hejazi, S H ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Drug film; Gentamicin; Paromomycin

Indexed keywords

GENTAMICIN; PAROMOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; FILM COATING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SKIN LEISHMANIASIS; TREATMENT OUTCOME;

LEISHMANIA MAJOR; MUS;

EID: 80052580036     PISSN: 17357020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Desjeux P. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q. 1992;45(2-3):267-75.
2. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006 Dec; 142 (12): 1575-9.
3. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M.Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3(5):e162. Epub 2006 Apr 18.
4. Croft SL, Coombs GH. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003; 19(11):502-8.
5. Asilian A, Jalayer T, Nilforooshzadeh M, Ghassemi RL, Peto R, Wayling S, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the IslamicRepublic of Iran. Bull World Health Organ. 2003; 81(5):353-9.
6. Jaafari MR, Bavarsad N, Bazzaz BS, Samiei A, Soroush D, Ghorbani S, et al. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob Agents Chemother. 2009; 53(6): 2259-65.
7. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res. 2006;123(3):399-410.
8. Armijos RX, Weigel MM, Calvopiña M, Mancheno M, Rodriguez R (2004). Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. 91(2): 153-160.
9. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Neg Trop Dis. 2009;3(5):e432.Epub 2009May 5.
10. Khamesipour A, Rafati S, Davoudi N, Mahboudi F and Modabber F. Leishmaniasis vaccine candidates for development: Global Overview, Indian J Med Res 123, March 2006, pp 423-438.
11. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Kieny MP, Tanner M. First generation leishmaniasis vaccines: a review of field efficacy trials. vaccine.2008 9;26(52):6759-67.Epub 2008 Oct 23.
12. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996; 14(5):417-23.
13. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Smith PG. Efficacy of killed wholeparasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009 30; 27(35):4747-53. Epub 2009 Jun 18.
14. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol. 2007;57(2):335.e1-29. Epub 2007 Mar 6.
15. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis. 2007 Apr 24;6:3.
16. Buffet P, Caumes E, Gentilini M. [Treatment of localized cutaneous leishmaniasis]. Ann Dermatol Venereol. 1994; 121(6-7): 503-11.
17. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 1995;53(6):648-51.
18. Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol. 2005;15(2):85-7.
19. Grogl M, Schuster BG, Ellis WY, Berman JD. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol. 1999; 85(2):354-9.
20. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J TropMed Hyg. 2002;66(2):147-51.